Crescent Biopharma Inc. has announced a series of leadership appointments as it bolsters its team with experienced professionals in oncology drug development and biotech operations. Joshua Brumm has been named chief executive officer and joins the board of directors, while Jonathan McNeill, M.D., takes on the role of president and chief operating officer. Ellie Im, M.D., has been appointed chief medical officer, Rick Scalzo, MBA, as chief financial officer, Jan Pinkas, Ph.D., as chief scientific officer, Amy Reilly as chief communications officer, and Tanya Sengupta, MBA, as executive vice president, chief of strategy and operations. Additionally, David Lubner has joined the board of directors. These changes are part of Crescent's strategy to advance its therapeutic pipeline for solid tumors.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。